The IRAK4 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HeLa human cervical adenocarcinoma cell line, with targeted disruption of the IRAK4 gene. This heterogeneous population collectively exhibits functional IRAK4 deficiency, enabling loss-of-function studies in innate immune signaling. The polyclonal format retains genetic diversity, facilitating robust population-based assays without clonal biases. The CRISPR/Cas9-mediated gene disruption impairs IRAK4 signal transduction, providing a platform for interrogating TLR/IL-1R pathways, inflammatory cytokine production, and cancer cell signaling.
HeLa cells originate from an HPV18-positive human cervical adenocarcinoma, providing an epithelial tumor model with well-characterized growth properties. These cells express Toll-like receptors and interleukin-1 receptors, making them suitable for innate immune studies in a cancerous context. HPV18 oncoproteins E6 and E7 inactivate p53 and Rb, adding complexity to signaling analyses. The IRAK4 knockout derivative enables dissection of immune signaling modules within this widely used model, and the adherent morphology and efficient transfection support diverse biochemical assays.
IRAK4 is a serine/threonine kinase that functions as a critical adaptor in the MyD88-dependent signaling cascade downstream of TLRs and IL-1R. It interacts with MyD88 and phosphorylates IRAK1, leading to TRAF6 recruitment and activation of TAK1 and the IKK complex, which drive NF-??B and MAPK (ERK, JNK, p38) pathways. IRAK4 also associates with the inhibitory factor Tollip. Gene disruption impairs signal transmission at this checkpoint, attenuating downstream responses to TLR ligands or IL-1 stimulation, and providing a loss-of-function model for pathway analysis.
In HeLa cells, IRAK4 knockout creates a tool for studying crosstalk between HPV-driven oncogenesis and innate immune signaling. HeLa cells maintain functional TLR/IL-1R pathways, and loss of IRAK4 modulates inflammatory cytokine production, offering insights into tumor microenvironment interactions. This model enables investigation of IRAK4 deficiency phenotypes, including altered NF-??B and MAPK responses to stimuli like LPS or IL-1??, relevant to inflammatory diseases, immunodeficiency, and cervical cancer. The polyclonal population permits assessment of signaling heterogeneity without clonal artifacts.
These cells support a variety of assays: Western blotting for phosphorylation events (e.g., I??B??, p38), RT-qPCR for cytokine transcripts, ELISA for IL-6 or TNF-??, NF-??B reporter assays, co-immunoprecipitation of MyD88 complexes, and flow cytometry for phospho-proteins. Applications include drug target validation, IRAK4 inhibitor screening, and comparative immune studies. For further information or to discuss specific experimental applications, please contact Ascent Research.
